BIGG

Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments

England. National Institute for Health and Care Excellence.

Año de publicación: 2023

Evidence-based recommendations on ripretinib (Qinlock) for treating gastrointestinal stromal tumour in adults after 3 or more treatments.

Cost-Benefit Analysis, Inhibitors, Tyrosine Kinase/therapeutic use, Gastrointestinal Stromal Tumors/drug therapy

Texto completo

WordPress version 4.9.8
BVS-Site Plugin version 0.6.0